Book a Meeting

Non-Fucosylated Anti-Human IL13 (ABT-308) Therapeutic Antibody (CAT#: BioBet-1047ZP) Datasheet

Target
IL13
Isotype
IgG
Description
ADCC-Enhanced anti-IL13 (ABT-308) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Eosinophilic Esophagitis
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced IL13 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IL13
Full Name
interleukin 13
Background
This gene encodes an immunoregulatory cytokine produced primarily by activated Th2 cells. This cytokine is involved in several stages of B-cell maturation and differentiation. It up-regulates CD23 and MHC class II expression, and promotes IgE isotype switching of B cells. This cytokine down-regulates macrophage activity, thereby inhibits the production of pro-inflammatory cytokines and chemokines. This cytokine is found to be critical to the pathogenesis of allergen-induced asthma but operates through mechanisms independent of IgE and eosinophils. This gene, IL3, IL5, IL4, and CSF2 form a cytokine gene cluster on chromosome 5q, with this gene particularly close to IL4.
Alternative Names
IL13; interleukin 13; P600; IL-13; interleukin-13
Gene ID
3596
UniProt ID
Q9UK05
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with IL13 include Asthma and Allergic Rhinitis.
Related Pathways
Its related pathways are Immune response Fc epsilon RI pathway and PEDF Induced Signaling.
Function
Cytokine. Inhibits inflammatory cytokine production. Synergizes with IL2 in regulating interferon-gamma synthesis. May be critical in regulating inflammatory and immune responses. Positively regulates IL31RA expression in macrophages (By similarity).
Post-translational modifications
Glycosylation at Asn52, Asn63, Asn71, and Asn86
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
ABT-308
Host
Humanized
Species Reactivity
Human
Description
RPC4046 is a monoclonal antibody currently being studied in a Phase 2 trial for the treatment of eosinophilic esophagitis (EoE). RPC4046 is directed against the interleukin-13 (IL-13) target, which has been validated in other allergy-related disorders including asthma. The development program for RPC4046 builds upon competencies in immunology and GI diseases.
Indication
Eosinophilic Esophagitis

Eosinophilic Esophagitis

Related Products

Highly Galactosylated Anti-IL13 (Anrukinzumab) Antibody (CAT#: BioBet-GA-286ZP)
Non-Fucosylated Anti-Human IL13 (13C5. 5) Therapeutic Antibody (CAT#: BioBet-1048ZP)
Non-fucosylated Anti-Human IL13 (Lebrikizumab) Therapeutic Antibody (CAT#: BioBet-285ZP)
Highly Galactosylated Anti-IL13 (Lebrikizumab) Antibody (CAT#: BioBet-GA-285ZP)
Highly Galactosylated Anti-IL13 (Tralokinumab) Antibody (CAT#: BioBet-GA-284ZP)
Non-Fucosylated Anti-Human IL13 (RPC4046) Therapeutic Antibody (CAT#: BioBet-1046ZP)
Highly Galactosylated Anti-IL13 (Dectrekumab) Antibody (CAT#: BioBet-GA-283ZP)
Non-fucosylated Anti-Human IL13 (Tralokinumab) Therapeutic Antibody (CAT#: BioBet-284ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany